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Purpose: To assess if a polyphenol compound supplementation (Vertigoval®) could improve
residual dizziness earlier after benign paroxysmal positional vertigo (BPPV) and relieve
patients from this disabling symptomatology.
Methods: In this prospective, multicentric study, 127 patients were randomized in the
treatment group (TG), who received a 60-day supplementation, while 131 patients were
randomized in the control group (CG), who did not receive any medication. The dizziness
handicap inventory (DHI) score, static posturography, and the visual analog scale (VAS) for
both dizziness (D-VAS) and nausea/vomit (N/V-VAS) were used as measures of outcome at
baseline and after 30 and 60 days. Patients were asked about efficacy and tolerance to the
treatment. Side effects were examined.
Results: A statistically significant greater decrease was established in the TG for DHI, D-
VAS, and N/V-VAS compared to the CG. On the other hand, static posturography did not
show statistical differences between the two groups, though a better clinical improvement
after 60-day supplementation was shown in the TG in comparison to the CG. We counted
mild side effects in only 2 patients. Most patients reported an excellent or good efficacy and
tolerance to the treatment.
Conclusion: Residual dizziness is a frequent condition of unknown origin that manifests as
persistent disabling imbalance after successful repositioning maneuvers for BPPV. The
decreasing postural control can affect the quality of life, contributing to falling and psycho-
logical problems. The supplementation with the polyphenol compound used in our study is
safe, manageable, and appeared to be able to reduce subjective symptoms and improve
instability earlier, decreasing the risk of potential complications.
Keywords: residual dizziness, benign, paroxysmal positional vertigo, BPPV, Vertigoval®
Introduction
Benign paroxysmal positional vertigo (BPPV) represents the most frequent vestib-
ular disorder in neuro-otological clinical practice with a prevalence in the general
population of about 2.4%.1,2
Even if this disorder may arise at any time of life, it rarely manifests in
adolescents, resulting more frequently in adults and elderly people. The peak of
incidence is around the fifth to seventh decade of life.2–4
Recurrent, brief and violent crises of true vertigo triggered by horizontal and
vertical movements of the head characterize the disorder. While the etiology of
BPPV has still not been fully understood and is classified as idiopathic in more than
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70% of cases,3 the pathogenesis of BPPV is on the other
hand almost certain: it may be identified in the detachment
of otoliths and in their displacement in one of the three
semicircular canals.5
A careful anamnesis normally addresses the diagnosis
of BPPV. The diagnosis will be confirmed by the clinical
examination of the patient that employs specific diagnostic
maneuvers according to which of the canals is involved.
While the Dix-Hallpike maneuver is used in order to
identify otoliths inside the posterior semicircular canal
(PSC), the supine head roll test is used for the horizontal
semicircular canal and the head-hanging maneuver for the
anterior semicircular canal. A proper diagnostic approach
means avoiding a series of useless and costly instrumental
tests and enables clinicians to go ahead swiftly with the
treatment.
The importance of timely recognition of BPPV derives
also from the high incidence of this pathology in the
elderly. This disorder prevents the capacity to carry out
normal routine daily activities determining a significant
increase in the risk of falling and consequent injury.6
Also, the treatment is through maneuver able to bring
the detached otoliths back to the utricle. Most patients
have a good recovery after the treatment.7 However, up
to two-thirds of patients may perceive a prolonged and
handicapping instability, lightheadedness and malaise also
known as “residual dizziness.”8 This residual symptoma-
tology after the resolution of BPPV is variably described
among patients. Some patients also complain of nausea
and vomiting. Previous studies reported an association
with a condition of stress of the subject that may be
correlated with the duration of the BPPV and number of
recurrences.8,9 Some authors reported the duration of the
residual symptoms of about 6–20 days.8–10 However, some
patients recover later than others and some of these still
present symptoms after 1 and 2 months.2,11 To our knowl-
edge, there is no accordance in the literature about any
drug or any other measure to approach this residual dis-
abling symptomatology.
In this study, we report the effect of 30- and 60-day
supplementation with a polyphenol compound
(Vertigoval®, Valeas, Milan, Italy) in patients with
residual symptoms after successfully treated BPPV.
Our main aim was to assess if this supplementation
could earlier improve symptoms in this category of
patients and relieve from the handicapping, and poten-
tial cause of fall, instability.
Materials and methods
In this prospective, multicentric, randomized study, 290
patients were recruited from different centers in Italy
between January 2017 and November 2017. Participating
centers were Benevento, Cagliari, Catanzaro, Genova,
Matera, Milan, Naples, Pisa, Rome, and Turin. The enroll-
ment of patients was made according to a randomization
list taking into account the ratio 1:1 between the two
groups of patients having the foresight to balance the
two groups in each center. For this purpose, we have
utilized the Lehmer algorithm using the number generator
as reports in the Emilia Romagna sites (http://wwwservizi.
regione.emilia-romagna.it/generatore/).
This study was approved by the Ethics Committee of
the AOUP (Azienda Ospedaliero-Universitaria Pisana).
All the patients belonging to the study group under-
went only routinely performed tests, without invasive or
experimental procedures. Written informed consent was
obtained from all participants and the study was conducted
in accordance with the Declaration of Helsinki.
Inclusion criteria were the presence of dizziness even-
tually associated with neurovegetative symptoms after
canalolithiasis of PSC BPPV2 successfully treated using
canalith repositioning procedures (paroxysmal positional
nystagmus is no more detectable by using an infrared/
video googles). The age had to be between 20 and 80
years old. Exclusion criteria were a post-traumatic or a
post-neuritis BPPV, central nervous system disease, alco-
hol or drug addiction, uncontrolled hypertension, hypoten-
sion, or thyroid disease, severe coronary artery disease,
severe renal and/or hepatic impairment, antiplatelet and/or
anticoagulant therapy, pregnant or breastfeeding, chronic
instability pre-existing at the onset of BPPV, known intol-
erance to the components of the supplementation, and poor
compliance.
The recruited patients were randomized in the treat-
ment group (TG), who took the polyphenol compound
containing the recommended daily intake (150 mg), one
tablet two times in a day away from meals for 60 days.
The supplementation is a polyphenol compound contain-
ing ViNitrox, Vitamin B6, Citicoline, Melissa officinalis,
and Ginger. Compliance with supplementation and side
effects were examined as self-reported by patients.
Patients were also asked about efficacy and tolerance to
the treatment as excellent, good, sufficient, or poor. The
remaining patients were randomized in the control group
(CG), who did not receive any supplementation.
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We evaluated all patients on the day of the recruitment
(T0), after 30 (T30) and 60 (T60) days, by performing
Dix-Hallpike maneuvers in order to exclude the presence
of recurrence of BPPV.
The Italian version of the dizziness handicap inventory
(DHI) score,12 static posturography, and the VAS for both
dizziness (D-VAS) and nausea/vomit (N/V-VAS) were
used as measures of outcome.
The DHI constitutes one of the most commonly used
measures to assess dizziness, and it is based on patient’s
reported outcome. As known, the self-assessment ques-
tionnaire is formed by 25 items with a total score ranging
from 0 to 100 on the basis of symptoms frequency.
Static posturography was performed by employing a
dedicated device (Standard Vestibology Platform, SVeP
stabilometric platform, Amplifon, Italy). The patients
were asked to maintain their balance on a support, either
rigid or with a 10-cm rubber foam applied on, with the
eyes open and eyes closed. For each condition, the follow-
ing parameters were considered: the length (L) of the
oscillations, expressed in millimeters and represented by
the entire distance covered by the center of pressure of the
subject, which is an index of the energy spent; the surface
(S) of the body sway, expressed in square millimeters and
represented by the confidence ellipse containing 90% of
the sample position, indicating the precision of the system.
The software automatically provided all measures.
Finally, patients were interviewed about their subjec-
tive sensation of dizziness and nausea/vomit, which were
reported using the D-VAS and the N/V-VAS, respectively.
The two end-points of the VAS were 0 (no sensation) and
100 (disabling and continuous sensation).
Statistical analysis
For each group and for each measure of outcome, we calcu-
lated the mean and the standard error of mean (SEM). For all
the measures of outcome, we assessed differences inside
each group within the timeframe using the paired samples
Student T-test. Differences between the TG and the CG were
evaluated using the independent sample Student T-test. For
the DHI, we also provided the absolute difference (mean of
the difference, delta) and the SEM within the established
timeframe in order to assess differences between the two
groups. We also determined the impact of age on DHI
score classifying patients into one of the three age groups:
younger adults (YA, age ≤40 years), middle age adults (MA,
age 41–60 years), or older adults (OA, age >60 years). DHI
and VAS time profile of treatment response have been done
using ANOVA for repeated measures and interaction treat-
ment*time has been also included in the model. Significance
was set at P≤0.05.
Results
Among the 290 patients recruited, 32 (11%) were dropped
out and were not considered for the statistical analysis.
Conditions below the drop out were the presence of a
recurrence in 2 cases (both patients belonged to the TG)
and the occurrence of side effects in 2 cases. Among these,
epigastric pain and agitation. The other patients were lost
to the follow-up. However, the drops out were good
balanced between the two groups having 15 patients in
the TG and 17 patients in the CG. None of the enrolled
patients suffered serious adverse events or had to change
the basal therapy for new illnesses. Among the remaining
258 patients, 127 were randomized in the TG and 131 in
the CG (Figure 1). In the TG, the average age was 50.6
(22–80) and there were 70 females and 57 males. In the
CG, the average age was 50.2 (20–80) and there were 77
females and 54 males. The period between the onset of
symptoms and the enrollment of patients was 1–10 days.
No significant differences were present at baseline
between the two groups about any of the considered out-
come measures (P>0.05). Both groups showed a statisti-
cally significant improvement of the DHI scores (P≤0.001)
both after 30 and after 60 days (Table 1). This improve-
ment was greater in the TG (P≤0.001) when we took into
Enrollment
Pts enrolled (n=290)
Pts randomized (n=290)
Allocation
T30
TG (n=142)
T60
CG (n=148)
Drop-out (n=13)
Lost (n=13)
Drop-out (n=4)
Lost (n=4)
Analyzed (n=131)Analyzed (n=127) Analysis
•
•
Drop-out (n=7)
Drop-out (n=8)
Occurence (n=1)
Occurence (n=1)
Side effects (n=2)
Lost (n=6)
Lost (n=5)
•
•
•
•
•
Figure 1 Flow diagram demonstrating patients (Pts) enrollment and progress in the
randomized controlled trial.
Abbreviations: TG, treated group; CG, control group; T30, after 30 days; T60
after 60 days.
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account the delta: at T30 −38% for CG and −56% for TG
and at T60 −50% for CG and −75% for TG. Moreover, a
difference (P≤0.001) between CG and TG was detected
also at T60 when the mean values of score were consid-
ered. Results are shown in detail in Table 1. ANOVA for
repeated measures carried out on DHI values showed a
significant interaction between treatment*time (P=0.05),
meaning a different profile of treatment response between
the two group of patients in favor of the group treated.
About the impact of age onDHI, the differences observed
both at T30 and T60 between CG and TG were less greater
for YA than those observed for MA and OA patients (P≤0.01
and P≤0.001). Data are reported in detail in Table 2.
The D-VAS and N/V-VAS assessment in both groups
showed a statistically significant improvement (P≤0.001)
of the baseline (T0) scores both after 30 and after 60 days
(Table 4). The comparison between groups showed a
greater decrease in the TG respect to the CG (P≤0.001,
P≤0.01 only for N/V-VAS at T30). ANOVA for repeated
measures showed a different result in the interaction treat-
ment*time results between D-VAS and N/V-VAS. The
interaction was statistically significant (p=0.03) only in
D-VAS.
The difference % vs T0 for D-VAS are at T30 −25%
for CG and −49% for TG and at T60 −44% for CG and
−81% for TG. The difference % vs T0 for N/V-VAS are at
T30 −39% for the CG and −58% for TG and at T60 −62%
for CG and −87% for TG. Results about D-VAS and N/V-
VAS are summarized in Table 3.
The static posturography assessment in both groups
(CG and TG) showed at each time (T30 and T60) always
an improvement in L and S both when the measure was
carried on rigid or soft support and when the eyes were
kept open or closed. When measures were made on soft
support, the TG seemed to show a better improvement
than CG. No statistical differences between groups were
found at each time of measurement. All the results about
static posturography are presented in detail in Table 4.
Efficacy and tolerance to the polyphenol compound
were reported as excellent or good in 81% and 94% at
T30 and 91% and 98% at T60 of patients, respectively.
Discussion
Residual dizziness is a common experience that manifests
as persistent imbalance after successful repositioning man-
euvers for BPPV. These symptoms may affect the quality
of life and prevent carrying out daily activities. The
decreasing postural control can contribute to falling and
psychological problems.13 Although many hypotheses
have been postulated, the origin of this disturbance is not
yet clear.10 Several medications have been proposed to
approach these symptoms14–17 but nothing has yet proved
to provide relief for residual dizziness compared to
placebo.10 The most used molecule to approach residual
dizziness after BPPV is betahistine dihydrochloride, but its
results are conflicting. Guneri and Kustutan14 found that
48 mg of betahistine daily, in addition to Epley maneuver,
gave more effective results than Epley maneuver alone or
combined with placebo in improving symptoms. On the
other hand, in the randomized controlled clinical trial by
Acar et al15, the authors did not find any difference
between patients who took betahistine, trimetazidine or
gingko biloba and patients who did not receive any
medication.
Table 1 Results of the assessment with dizziness handicap inventory (DHI) score at baseline (T0) and after 30 days (T30) and after 60
days (T60) in the treated group (TG) and in the control group (CG). Mean ± standard error of mean (SEM) of DHI values and absolute
difference versus T0 value (delta)
Patients (n) T0
Mean ± SEM
T30
Mean ± SEM
T60
Mean ± SEM
CG 131 DHI values
Paired t test
(Absolute delta vs T0)
38.53±1.19
–
–
24.06±0.96
***
(−14.47±0.92)
17.18±0.29
***
(−21.40±1.24)
TG 127 DHI values
Paired t test
(Absolute delta vs T0)
41.09±1.31
–
–
20.74±1.21
***
(−20.35±14.36)
10.47±1.05
***
(−30.61±1.33)
CG vs TG
Independent t test
DHI values ns ns ***
Absolute delta vs T0 – *** ***
Notes: ns, P>0.05; ***P≤0.001.
Abbreviation: ns, not significant.
Casani et al Dovepress
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Kim et al16 investigated the role of vestibular suppres-
sant in a randomized controlled trial. According to the
authors, dimenhydrinate could be helpful in preventing
residual dizziness. However, side effects of this molecule
need to be known and its use is reserved to selected
patients for a limited number of days. In the same way,
there is no consensus about the use of anxiolytic suggested
by Jung et al17.
In this multicentric study, our main purpose was to
assess if a polyphenol compound could provide benefit to
the category of patients studied. The analysis has been
carried out on a great sample of patients, and to our
knowledge, there are no previous similar experiences in
the literature. Because of the features of this medication, it
is overall safe and can be easily employed to approach also
elderly that are mostly included in this category of
patients.
Our results showed an overall progressive improve-
ment of all the measures of outcome considered in both
groups after 30 and 60 days. This was expected and
underlines the natural relief of symptoms in most
patients. However, we noticed a more significant
improvement in the TG, in particular after 60 days of
treatment with the polyphenol compound. The decision
to evaluate up to 60 days the effect of the polyphenol
Table 2 Impact of age on dizziness handicap inventory (DHI)
score in the treated group (TG) and in the control group (CG).
Mean of absolute difference versus T0 (delta)
Absolute delta
vs T0
(mean value)
Age
(years)
Group Patients (n) T30 T60
≤40
(Younger Adults)
CG 29 −15.2 −20.1
TG 24 −18.6 −28.9
Independent t test ns *
>40 to ≤60
(Middle Age Adults)
CG 73 −15.0 −22.9
TG 74 −20.7 −30.2
Independent t test ** **
>60
(Older Adults)
CG 28 −12.9 −19.43
TG 27 −21.9 −33.3
Independent t test ** ***
Notes: ns, P>0.05; *P≤0.05; **P≤0.01; ***P≤0.001.
Abbreviations: T0, baseline; T30, after 30 days; T60 after 60 days.
Table 3 Results of the assessment with D-VAS (dizziness VAS) and N/V-VAS (nausea and vomit VAS) at baseline (T0) and after 30
(T30) and 60 (T60) days in the treated group (TG) and in the control group (CG). Mean ± standard error of mean (SEM)
Patients (n) T0
Mean ± SEM
T30
Mean ± SEM
T60
Mean ± SEM
CG 97 D-VAS values
Paired t test
(% vs T0)
48.85±2.02
–
(–)
36.95±1.75
***
(−24.4%)
27.08±1.91
***
(−44.6%)
TG 94 D-VAS values
Paired t test
(% vs T0)
51.21±1.97
–
26.05±1.65
***
(−49.1%)
9.96±1.47
***
(−80.6%)
CG vs TG
Independent t test
ns *** ***
CG 97 N/V-VAS values
Paired t test
(% vs T0)
30.67±2.10
–
18.86±1.57
***
(−38.5%)
11.70±1.80
***
(−61.9%)
TG 94 N/V-VAS values
Paired t test
(% vs T0)
28.83±2.21
–
12.16±1.61
***
(−57.8%)
3.88±0.90
***
(−86.5%)
CG vs TG
Independent t test
ns ** ***
Notes: ns, P>0.05; **P≤0.01; ***P≤0.001.
Abbreviations: T0, baseline; T30, after 30 days; T60 after 60 days; ns, not significant..
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Table 4 Results of the assessment with static posturography at baseline (T0) and after 30 (T30) and 60 (T60) days in the treated group
(TG) and in the control group (CG). Mean ± standard error of mean (SEM)
Patients (n) T0
Mean ± SEM
T30
Mean ± SEM (%)
Paired t test
T60
Mean ± SEM (%)
Paired t test
S on rigid support with
the eyes open
CG n.67 302.7±28.3
–
264.4±20.9
(−12.7%)
*
239.9±18.2
(−20.7%)
*
TG 59 269.0±21.6
–
241.7±21.5
(−10.1%)
ns
191.9±17.7
(−28.7%)
***
S on rigid support with
the eyes closed
CG 67 530.1±70.5
–
419.2±26.2
(−20.9%)
*
384.7±27.4
(−27.4%)
*
TG 59 498.0±40.0
–
401.3±32.7
(−19.4%)
ns
329.7±26.0
(−33.8%)
***
S on soft
support with
the eyes open
CG 55 499.9±57.0
–
435.8±76.6
(−12.8%)
ns
364.5±58.82
(−27.1%)
*
TG 50 417.0±43.7
–
323.8±37.7
(−22.4%)
***
265.8±38.4
(−36.3%)
***
S on soft
support with
the eyes closed
CG 55 1014.0±151.4
–
878.1±120.2
(−13.4%)
ns
831.9±124.5
(−18.0%)
ns
TG 50 1471.0±259.4
–
1189.3±228.9
(−19.2%)
*
998.1±219.4
(−32.1%)
***
L on rigid support with
the eyes open
CG 67 386.5±31.6 349.6±31.1
(−9.5%)
**
324.0±31.4
(−16.2%)
***
TG 59 382.5±27.3 329.1±25.5
(−14.0%)
***
272.0±23.5
(−28.9%)
***
L on rigid support with
the eyes closed
CG 67 606.1±44.5 539.7±47.5
(−11.0%)
**
477.3±43.7
(−21.3%)
***
TG 59 613.1±42.6 532.1±40.7
(−13.2%)
***
413.2±33.2
(−32.6%)
***
L on soft
support with
the eyes open
CG 55 543.3±52.3 514.9±53.5
(−5.2%)
*
493.9±57.0
(−9.1%)
**
TG 50 510.8±46.3 433.8±41.4
(−15.1%)
***
366.0±38.7
(−28.3%)
***
(Continued)
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supplementation comes from a previous experience that
highlighted residual dizziness up to 60 days after suc-
cessful repositioning treatment in patients with BPPV.18
The treatment up to 60 days could keep under control
the possible exacerbations during the progressive vestib-
ular compensation that is very different among patients
because of multi-factor variables. The DHI time profiles
of the two groups (TG vs CG) are different, meaning a
different treatment response over time in favor of the
group treated with the polyphenol compound we used.
Patients enrolled in the TG showed a greater decrease of
the DHI score within the timeframe compared to
patients of the CG. The validity of this score is sup-
ported by a recent systematic review that describes the
DHI as a good and validated instrument applicable also
in adults with vestibular impairment.19 The supplemen-
tation seems to provide a greater relief from symptoms
in patients older than 40 years. Since a faster recovery
might decrease the risk of falling, which is above all
pronounced in older patients, this data are particularly
interesting.
The lowest subjective disturbance complained by
patients who took the supplementation is also supported
by both VAS. VAS constitutes a simple and rapid tool for
symptoms assessment.20 Both DHI and VAS provide use-
ful information about the influence of symptoms on the
quality of life of patients with vestibular dysfunction and,
together, may contribute to a better comprehension of the
clinical condition and assist monitoring of the therapeutic
approach. Surely, a lower perception of the disturbance
might prevent the potential psychological complications
described in this affection.
Tolerance and efficacy of the therapy were judged as
excellent and good by most patients. Side effects
manifested in a minority of patients with a mild sympto-
matology, making this medication overall sure and
manageable.
The results we found can be easily supported by the
components of the polyphenol compound we used.
Citicoline and Vitamin B6 might facilitate the function of the
central vestibular system having a protective effect on micro-
vascular circulation. Yet, Melissa seems to be able to potenti-
ate the gamma-aminobutyric acid (GABA) receptors
alleviating the stress, which has been counted among the
conditions below the residual instability after BPPV, as pre-
viously reported. The antiemetic power of ginger, on the other
hand, was known since antiquity. The last component is
ViNitrox, a synergistic combination of apple and grape poly-
phenols that has been demonstrated to have a remarkable
vasodilator effect through endothelial nitric oxide synthase
(NOS) and antioxidant activity. The combination seems effec-
tive in at least partially restoring themicrovascular impairment
in these patients improving also the cognitive function.
Usefully, a recent article published by Ulivi et al21 reports
that the supplementation for 60 days with the polyphenol
compound we studied reduces oxidative stress load in
patients with a pre-existing imbalance, improving dizziness
symptoms. Even if the study has been carried out on patients
suffering from chronic dizziness because of the underlying
small vessel disease, the mechanisms below the symptom’s
improvement in this category of patients can be the same able
to take relief to the patients recruited in our study.
To our knowledge, static posturography has never been
proposed and used as a measure to assess the outcome of
patients suffering from residual dizziness after BPPV.
Dynamic posturography has been rather employed by
Vaduva et al11 to promote vestibular compensation in a
recent study. The results obtained in our study are partially
Table 4 (Continued).
Patients (n) T0
Mean ± SEM
T30
Mean ± SEM (%)
Paired t test
T60
Mean ± SEM (%)
Paired t test
L on soft
support with
the eyes closed
CG 55 895.5±78.4 892.7±94.9
(−0.3%)
ns
832.9±99.0
(−7.0%)
ns
TG 50 1021.2±113.8 890.8±124.1
(−12.8%)
**
741.0±106.4
(−27.4%)
***
Notes: No statistically significant difference (Independent t test; P>005) between group in any comparison at each time (T0, T30, T60) was found. ns, P>0.05; *P≤0.05;
**P≤0.01; ***P≤0.001.
Abbreviations: S, surface; L, length; T0, baseline; T30, after 30 days; T60 after 60 days; ns, not significant.
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discordant. This can be due to the extremely complex
interactions among sensory, motor, and central processes
involved in posture and balance. The improved values in
both groups within the timeframe can be easily explained
by the natural and progressive improvement of the symp-
toms. However, also in this case, we detected a more
pronounced decrease in the TG as perhaps further confir-
mation of the beneficial effect of the supplementation.
The main limitation of our study is the non-double-
blinded design together with the lack of a placebo group
able to clarify if the results we found can be partially due to
the time passing. Surely, further studies are needed in order
to confirm the encouraging data detected in this study.
Conclusion
Residual dizziness is a frequent condition of unknown
origin that manifests as persistent disabling imbalance
after successful repositioning maneuvers for BPPV. The
decreasing postural control can affect the quality of life
contributing to falling and psychological problems.
Several medications have been proposed to approach
these symptoms but the results reported are conflicting.
The supplementation with the polyphenol compound
examined in our study is safe, manageable, and might be
able to reduce subjective symptoms and improve instabil-
ity earlier, decreasing the risk of potential complications.
Disclosure
The authors declare no conflicts of interest regarding this
article.
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